Search Results - Thomas R. MacGregor
- Showing 1 - 3 results of 3
-
1
-
2
Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations? by Bregt S Kappelhoff, Frank van Leth, Patrick Robinson, Thomas R. MacGregor, Ezio Baraldi, Francesco Montella, David Éverson Uip, Melanie Thompson, Darren Russell, Joep MA Lange, Jos H. Beijnen, Alwin D. R. Huitema
Published 2005Artigo -
3
A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir by Julie B. Dumond, Manoli Vourvahis, Nardin Rezk, Kristine B. Patterson, H.-C. Tien, Nicole White, Steven H. Jennings, Sun Ok Choi, J. Li, Michael J. Wagner, Ninh M. La‐Beck, Murray Drulak, John P. Sabo, Mark Castles, Thomas R. MacGregor, Angela D. M. Kashuba
Published 2010Artigo
Search Tools:
Related Subjects
Antiretroviral therapy
Human immunodeficiency virus (HIV)
Medicine
Pharmacology
Viral load
Virology
Efavirenz
Internal medicine
Nevirapine
Reverse-transcriptase inhibitor
Adverse effect
Biology
Drug
Drug resistance
Elimination rate constant
Environmental health
Gastroenterology
Gene
Genetics
Genotype
Hepatitis B virus
Inducer
Lamivudine
Multiple drug resistance
NONMEM
P-glycoprotein
Pharmacokinetics
Phenotype
Population
Ritonavir